These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1043 related items for PubMed ID: 22409231

  • 1. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [Abstract] [Full Text] [Related]

  • 2. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
    Snedecor SJ, Carter JA, Kaura S, Botteman MF.
    J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
    Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.
    Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands.
    Carter JA, Joshi A, Kaura S, Botteman MF.
    J Med Econ; 2011 Aug; 14(3):288-98. PubMed ID: 21469915
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.
    J Med Econ; 2013 Aug; 16(2):260-2. PubMed ID: 23176287
    [No Abstract] [Full Text] [Related]

  • 20. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.
    Terpos E, Jamotte A, Christodoulopoulou A, Campioni M, Bhowmik D, Kennedy L, Willenbacher W.
    J Med Econ; 2019 Aug; 22(8):766-776. PubMed ID: 30969797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.